302 related articles for article (PubMed ID: 33579941)
1. AA amyloid fibrils from diseased tissue are structurally different from in vitro formed SAA fibrils.
Bansal A; Schmidt M; Rennegarbe M; Haupt C; Liberta F; Stecher S; Puscalau-Girtu I; Biedermann A; Fändrich M
Nat Commun; 2021 Feb; 12(1):1013. PubMed ID: 33579941
[TBL] [Abstract][Full Text] [Related]
2. Cryo-EM fibril structures from systemic AA amyloidosis reveal the species complementarity of pathological amyloids.
Liberta F; Loerch S; Rennegarbe M; Schierhorn A; Westermark P; Westermark GT; Hazenberg BPC; Grigorieff N; Fändrich M; Schmidt M
Nat Commun; 2019 Mar; 10(1):1104. PubMed ID: 30846696
[TBL] [Abstract][Full Text] [Related]
3. Cryo-EM demonstrates the in vitro proliferation of an ex vivo amyloid fibril morphology by seeding.
Heerde T; Rennegarbe M; Biedermann A; Savran D; Pfeiffer PB; Hitzenberger M; Baur J; Puscalau-Girtu I; Zacharias M; Schwierz N; Haupt C; Schmidt M; Fändrich M
Nat Commun; 2022 Jan; 13(1):85. PubMed ID: 35013242
[TBL] [Abstract][Full Text] [Related]
4. Methods to study the structure of misfolded protein states in systemic amyloidosis.
Fändrich M; Schmidt M
Biochem Soc Trans; 2021 Apr; 49(2):977-985. PubMed ID: 33929491
[TBL] [Abstract][Full Text] [Related]
5. Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis.
Moderer T; Puşcalău-Gîrţu I; Haupt C; Baur J; Rodríguez-Alfonso A; Wiese S; Schmidt CQ; Malešević M; Forssmann WG; Ständker L; Fändrich M
Amyloid; 2023 Dec; 30(4):424-433. PubMed ID: 37431668
[TBL] [Abstract][Full Text] [Related]
6. Transmission of systemic AA amyloidosis in animals.
Murakami T; Ishiguro N; Higuchi K
Vet Pathol; 2014 Mar; 51(2):363-71. PubMed ID: 24280941
[TBL] [Abstract][Full Text] [Related]
7. Amyloid fibril structure from the vascular variant of systemic AA amyloidosis.
Banerjee S; Baur J; Daniel C; Pfeiffer PB; Hitzenberger M; Kuhn L; Wiese S; Bijzet J; Haupt C; Amann KU; Zacharias M; Hazenberg BPC; Westermark GT; Schmidt M; Fändrich M
Nat Commun; 2022 Nov; 13(1):7261. PubMed ID: 36433936
[TBL] [Abstract][Full Text] [Related]
8. Induction of murine AA amyloidosis by various homogeneous amyloid fibrils and amyloid-like synthetic peptides.
Liu Y; Cui D; Hoshii Y; Kawano H; Une Y; Gondo T; Ishihara T
Scand J Immunol; 2007 Nov; 66(5):495-500. PubMed ID: 17953525
[TBL] [Abstract][Full Text] [Related]
9. Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter.
Schulte T; Chaves-Sanjuan A; Mazzini G; Speranzini V; Lavatelli F; Ferri F; Palizzotto C; Mazza M; Milani P; Nuvolone M; Vogt AC; Vogel M; Palladini G; Merlini G; Bolognesi M; Ferro S; Zini E; Ricagno S
Nat Commun; 2022 Nov; 13(1):7041. PubMed ID: 36396658
[TBL] [Abstract][Full Text] [Related]
10. Protease resistance of
Schönfelder J; Pfeiffer PB; Pradhan T; Bijzet J; Hazenberg BPC; Schönland SO; Hegenbart U; Reif B; Haupt C; Fändrich M
Amyloid; 2021 Dec; 28(4):243-251. PubMed ID: 34338090
[TBL] [Abstract][Full Text] [Related]
11. Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo.
Husebekk A; Skogen B; Husby G; Marhaug G
Scand J Immunol; 1985 Mar; 21(3):283-7. PubMed ID: 3922050
[TBL] [Abstract][Full Text] [Related]
12. Aggregation of Mouse Serum Amyloid A Protein Was Promoted by Amyloid-Enhancing Factors with the More Genetically Homologous Serum Amyloid A.
Lin X; Watanabe K; Kuragano M; Tokuraku K
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494290
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of amyloid proteins.
Benson MD; Kluve-Beckerman B; Liepnieks JJ; Murrell JR; Hanes D; Uemichi T
Ciba Found Symp; 1996; 199():104-13; discussion 113-8. PubMed ID: 8915606
[TBL] [Abstract][Full Text] [Related]
14. Effect of amino acid variations in the central region of human serum amyloid A on the amyloidogenic properties.
Takase H; Tanaka M; Miyagawa S; Yamada T; Mukai T
Biochem Biophys Res Commun; 2014 Jan; 444(1):92-7. PubMed ID: 24440699
[TBL] [Abstract][Full Text] [Related]
15. Animal models for reactive amyloidosis.
Gruys E; Snel FW
Baillieres Clin Rheumatol; 1994 Aug; 8(3):599-611. PubMed ID: 7954864
[TBL] [Abstract][Full Text] [Related]
16. The pathogenesis and biochemistry of amyloidosis.
Cohen AS; Connors LH
J Pathol; 1987 Jan; 151(1):1-10. PubMed ID: 3550020
[TBL] [Abstract][Full Text] [Related]
17. Influence of C-terminal truncation of murine Serum amyloid A on fibril structure.
Rennegarbe M; Lenter I; Schierhorn A; Sawilla R; Haupt C
Sci Rep; 2017 Jul; 7(1):6170. PubMed ID: 28733641
[TBL] [Abstract][Full Text] [Related]
18. Recent insights into the pathogenesis of type AA amyloidosis.
van der Hilst JC
ScientificWorldJournal; 2011 Mar; 11():641-50. PubMed ID: 21403980
[TBL] [Abstract][Full Text] [Related]
19. Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis.
Westermark GT; Westermark P
FEBS Lett; 2009 Aug; 583(16):2685-90. PubMed ID: 19393650
[TBL] [Abstract][Full Text] [Related]
20. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.
Gillmore JD; Lovat LB; Persey MR; Pepys MB; Hawkins PN
Lancet; 2001 Jul; 358(9275):24-9. PubMed ID: 11454373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
